Biodesix stock plunges as life-sciences firm cuts sales projection
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that develops tools to detect lung disease, saw its stock price shed more than 35% of its value in early trading Thursday after the company cut millions from its 2025 fiscal-year revenue guidance.
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
Related Posts
-
Biodesix Inc. (Nasdaq: BDSX), a life-sciences company that specializes in developing tools to detect lung…
-
Edgewise Therapeutics plans to sell nearly 10 million shares of its common stock at $20.13,…
-
Foresight Diagnostics Inc., a Boulder-based cancer diagnostics company that specialized in the development of ultra-sensitive…
-
Enliven Therapeutics increased its research and development spending in the fourth quarter of fiscal 2024…
